

April 20, 2021

The changes in this bulletin apply to all groups that use the Lowest Net Cost Formulary. These changes include decisions that occurred as a result of our March 2021 Pharmacy and Therapeutics Committee (P&T) meeting. Members negatively impacted by one of these changes will be sent a letter in May.

FORMULARY UPDATES

Additions

These drugs will be added to the formulary effective July 1, 2021. **Bold** indicates a specialty drug.

Blenrep*	Kanjinti*	Onureg*	Vesicare LS
Dojolvi*	Kesimpta*#	Renflexis*	Zarxio*
Enspryng*	Monjuvi*	Ruxience*	Ziextenzo*
Evrysdi*#	Mvasi*	Tecartus*	Zirabev*
Fluocinonide Cream 0.1%	Mycapssa*	Trazimera*	
Gavreto*	Neulasta*	Truxima*	
Inflectra*	Neulasta Onpro*	Uplizna*	
Inqovi*	Nivestym*	Upneeq*	

* Requires Prior Authorization | # Quantity Limit

Tier Change

The drug **Tazorac** (gel and cream) will move from Tier 2 to Tier 3, effective July 1, 2021.

Exclusions

Accupril	Crestor	Lotrel	Tarka
Ala-Scalp Lotion 2%	Dapsone	Lovaza	Tenormin
Aldactone	Dermotic Oil	Lyrica	Timolol Gel Sol
Altace	Diovan HCT	Maxalt/MLT	Toprol XL
Arthrotec 75	Diovan	Mestinon	Tribenzor
Atripla	Dyazide	Micardis/HCT	Truvada
Avapro	Emtriva	Mobic	Veltin
Butrans/HR	Exforge	Norvasc	Viread
Caduet	Fenofibrate	Onfi Sus/Tab	Xeloda
Celebrex	Fosamax + D	Pravachol	Zestoretic
Celexa	Hyzaar	Procardia XL	Zestril
Ciprodex	Jadenu Sprkl Gra	Ranexa	Zocor
Cordran	Lasix	Relpax	Zomig
Corgard	Lipitor	Suboxone	
Cozaar	Lopressor	Symfi	

UTILIZATION MANAGEMENT (UM) PROGRAM UPDATES

Quantity Management

Effective July 1, 2021, we will implement the following quantity limits:

Eliquis

- 2.5 mg – 60 tablets/30 days
- 5 mg – 90 tablets/30 days

Evryski

- Dosing based on patient weight—Maximum daily dose of 8 tablets/day (240 tablets/30 days)

Kesimpta

- 1 syringe/30 days

Nurtec

- 8 tablets/30 days

Ubrelvy

- 10 tablets/30 days

Xarelto

- 2.5 mg – 60 tablets/30 days
- 10 mg – 30 tablets/30 days
- 15 mg – 60 tablets/30 days
- 20 mg – 30 tablets/30 days

Please direct questions to your PAI account executive.